CVS Health (CVS) shares lost ground in early trading Wednesday after the pharmacy giant slashed its 2024 earnings guidance again amid increased medical costs and announced the departure of the head of its Aetna unit.

The company lowered its 2024 guidance for 澳洲幸运5官方开奖结果体彩网:earnings per share (EPS) for a third straight quarter, to a range of $4.9ꩲ5 to $5.20 from at least $5.64 previously.

CVS reported second-quarter revenue of $91.23 billion, up 2.6% from a year ago, but 澳洲幸运5官方开奖结果体彩网:below forecasts, while EPS of $1.41 beat projections.

Medicare Claims, Drop in Star Ratings Hi🍃t Results

CVS struggled with a rise in Medicare claims during the quarter, and a drop in its 澳洲幸运5官方开奖结果体彩网:star ratings for those plans. 澳洲幸运5官方开奖结果体彩网:Medicare and Medicaid are both government-run programs that help cover health care costs♍, with Medicare open to Americans 65 and older or who meet certain criteria.

Aetna President Leaves

The company also said that "based on the current performance and outlook for the Health Care Benefits segment," Aetna President Brian Kane is leaving, and CVS CEO Karen Lynch will take over management of the business and oversee it with CFO Tom Cowhey. 

CVS shares were down 2% at $57.06 in early trading Wednesday following the news and have lost over 27% of the🌺ir value s🌌o far this year.